Cardiac hypertrophy is enhanced in PPARα-/- mice in response to chronic pressure overload

Cardiovascular Research

Volumn 78, Issue 1, 2008, Pages 79-89

  Smeets, Pascal J H ^a   Teunissen, Birgit E J ^a   Willemsen, Peter H M ^a   Van Nieuwenhoven, Frans A ^a   Brouns, Agnieszka E ^a   Janssen, Ben J A ^a   Cleutjens, Jack P M ^a   Staels, Bart ^b,c,d   Van Der Vusse, Ger J ^a   Van Bilsen, Marc ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UNIV LILLE   (France)

Author keywords

Fibrosis; Hypertrophy; Inflammation; Metabolism; PPAR ; Pressure overload

Indexed keywords

ALPHA ACTIN; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; CYCLOOXYGENASE 2; DOBUTAMINE; GELATINASE A; INTERLEUKIN 6; LONG CHAIN FATTY ACID COENZYME A LIGASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE METABOLISM; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

3-HYDROXYACYL COA DEHYDROGENASES; ACTINS; ANIMALS; AORTA, THORACIC; ATRIAL NATRIURETIC FACTOR; COENZYME A LIGASES; COLLAGEN TYPE I; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-6; LIGATION; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; PPAR ALPHA; RNA, MESSENGER; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 41149087688     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn001     Document Type: Article

References (41)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
2. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-367.
3. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 2004;64:507-515.
4. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 2005;38:505-515.
5. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995;96:1093-1099.
6. Palmer JN, Hartogensis WE, Patten M, Fortuin FD, Long CS. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995;95:2555-2564.
7. Gupta S, Young D, Sen S. Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H20- H29.
8. Higuchi Y, Chan TO, Brown MA, Zhang J, DeGeorge BR Jr, Funakoshi H et al. Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 2006;290:H590-H598.
9. Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 2006;17:321-327.
10. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-32054.
11. Smeets PJ, Planavila A, Vusse Van der GJ, Van Bilsen M. Peroxisome proliferator-activated receptors and inflammation: take it to heart. Acta Physiol 2007;191:171-188.
12. van Bilsen M, Vusse van der GJ, Gilde AJ, Lindhout M, Lee van der KA. Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression. Mol Cell Biochem 2002;239:131-138.
13. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
14. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR-alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004;36:295- 304.
15. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006;41:318-329.
16. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL et al. Targeted disruption of the alpha isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012- 3022.
17. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991;88:8277-8281.
18. De Celle T, Cleutjens JP, Blankesteijn WM, Debets JJ, Smits JF, Janssen BJ. Long-term structural and functional consequences of cardiac ischaemia-reperfusion injury in vivo in mice. Exp Physiol 2004;89:605-615.
19. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003;284:H364- H371.
20. Lutgens E, Daemen MJ, de Muinck ED, Debets J, Leenders P, Smits JF. Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc Res 1999;41:586-593.
21. Teunissen BE, Smeets PJ, Willemsen PH, De Windt LJ, Vusse Van der GJ, Bilsen Van M. Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res 2007;75:519-529.
22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Roy Van N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:1-11.
23. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. Base relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
24. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998;273:5678-5684.
25. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999;96:7473-7478.
26. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001;50:2809-2814.
27. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000;275:22293-22299.
28. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 2002;277:26089-26097.
29. Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G et al. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol 2006;291:H161-H166.
30. Guellich A, Damy T, Lecarpentier Y, Conti M, Claes V, Samuel JL et al. Role of oxidative stress in cardiac dysfunction of PPAR(alpha)-/- mice. Am J Physiol Heart Circ Physiol 2007;293:H93-H102.
31. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112:2339-2346.
32. Panagia M, Gibbons GF, Radda GK, Clarke K. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 2005;288:H2677-H2683.
33. Vusse van der GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992;72:881-940.
34. Pruimboom-Brees I, Haghpassand M, Royer L, Brees D, Aldinger C, Reagan W et al. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. Am J Pathol 2006;169:750-760.
35. Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2007;27:1276-1282.
36. Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 2004;109:904-910.
37. Liang F, Wang F, Zhang S, Gardner DG. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 2003;144:4187-4194.
38. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS et al. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 2007;49:1084-1094.
39. Degens H, de Brouwer KF, Gilde AJ, Lindhout M, Willemsen PH, Janssen BJ et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 2006;101:17-26.
40. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW et al. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 2004;287:H1712-H1720.
41. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 2001;98:6668- 6673.